QuidelOrtho (QDEL) reported Q3 2025 adjusted EPS of $0.80 and revenues of $699.9 million, both exceeding consensus estimates, with adjusted operating margin expanding 70 basis points to 17.1% due to lower expenses. While Labs and Immunohematology segments showed solid growth, overall revenue declined 3.8% year-over-year, primarily driven by a significant drop in respiratory product sales. Despite the quarterly beat, the company's reiterated 2025 adjusted EPS guidance of $2.00-$2.15 remains below the Zacks Consensus Estimate, signaling ongoing challenges.
QuidelOrtho (QDEL) reported adjusted Q3 2025 EPS of $0.80 and revenues of $699.9 million, both surpassing Zacks consensus estimates by 56.9% and 5.3% respectively. Despite this beat, reported revenues declined 3.8% year-over-year, and the company posted a significant GAAP loss per share of $10.78, a substantial increase from $0.30 in the prior year. Adjusted operating margin expanded by 70 basis points to 17.1%, driven by lower expenses and improved efficiency, which partially offset a 50 bps contraction in adjusted gross margin. Segmental performance was mixed, with Labs revenues growing 5% and Immunohematology revenues increasing 7.7% on a reported basis, while Non-Respiratory revenues collectively rose 4.6%. However, these gains were overshadowed by a sharp 32.1% decline in Respiratory revenues to $112.3 million, and significant drops in Donor Screening (down 47.3%), Point of Care (down 20%), and Molecular Diagnostics (down 14.3%). Geographically, EMEA, China, and Other regions showed growth, offsetting a 12.6% decline in North America. The company's financial position shows increased leverage, with total debt rising to $2.66 billion from $2.61 billion quarter-over-quarter, and cash and cash equivalents decreasing to $98.1 million from $151.7 million. Furthermore, cumulative net cash used in operating activities was $26.7 million, a reversal from net cash provided a year ago. QuidelOrtho reiterated its 2025 revenue guidance of $2.68 billion-$2.74 billion, aligning with consensus, but its adjusted EPS guidance of $2.00-$2.15 falls below the Zacks Consensus Estimate of $2.28. This mixed performance, characterized by a top-line beat driven by cost controls and specific segment strength but undermined by overall revenue contraction, significant GAAP losses, and a downward revision relative to consensus EPS guidance, contributes to a moderately negative sentiment. The company currently holds a Zacks Rank #5 (Strong Sell), reflecting concerns about its fundamental outlook despite some operational efficiencies.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.50
Ticker Sentiment
